Cargando…

HCC surveillance results in earlier HCC detection: results from an Indian cohort

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide, with an increased incidence in South Asia. In order to describe the effect of surveillance for HCC with biannual ultrasound and alpha-fetoprotein (AFP) on diagnosis and survival in an Indian population a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kohli, Anita, Murphy, Allison A, Agarwal, Chirdeep, Shivakumar, Bhavana, Kottilil, Shyam, Polis, Michael A, Subramanian, G Mani, Midha, Vandana, Goyal, Omesh, Desai, Srinivas, Sood, Ajit, Shah, Samir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209002/ https://www.ncbi.nlm.nih.gov/pubmed/25392781 http://dx.doi.org/10.1186/2193-1801-3-610

Ejemplares similares

New Therapeutics for HCC: Does Tumor Immune Microenvironment Matter?
por: Khanam, Arshi, et al.
Publicado: (2022)

HCC, diet and metabolic factors: Diet and HCC
por: Montella, Maurizio, et al.
Publicado: (2011)

Immune System and Hepatocellular Carcinoma (HCC): New Insights into HCC Progression
por: Kotsari, Maria, et al.
Publicado: (2023)

Hepatocellular carcinoma: HCC
por: Blum, Hubert E.
Publicado: (2011)

Intratumor heterogeneity in HCC
por: Friemel, Juliane, et al.
Publicado: (2015)

Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring
por: Sun, Na, et al.
Publicado: (2020)

GATA3 is downregulated in HCC and accelerates HCC aggressiveness by transcriptionally inhibiting slug expression
por: Zhang, Zhuoliang, et al.
Publicado: (2021)

Olfm4 Is Highly Expressed in HCC Patients and as a Biomarker and Therapeutic Target for HCC
por: Wei, Yulong, et al.
Publicado: (2021)

GATA3 is downregulated in HCC and accelerates HCC aggressiveness by transcriptionally inhibiting slug expression
por: Zhang, Zhuoliang, et al.
Publicado: (2021)

Decision making in elderly HCC
por: Trovato, M A, et al.
Publicado: (2011)

Molecular network of HCC aggressiveness
por: Kim, Sang Geon, et al.
Publicado: (2015)

The Epigenetic Regulation of HCC Metastasis
por: Han, Tae-Su, et al.
Publicado: (2018)

Strategies for HCC target discovery
por: Molina-Sánchez, Pedro, et al.
Publicado: (2017)

Inflammatory Mechanisms of HCC Development
por: Refolo, Maria Grazia, et al.
Publicado: (2020)

Human Hepatocellular Carcinoma (HCC)
por: Buonaguro, Luigi
Publicado: (2020)

The paradox of immunotherapy in NASH-HCC
por: Peng, Yao, et al.
Publicado: (2021)

HCC diagnosis DFP report
Publicado: (2021)

Diabetes medications and risk of HCC
por: Plaz Torres, Maria Corina, et al.
Publicado: (2022)

HCC: RNA-Sequencing in Cirrhosis
por: Wang, Haoyu, et al.
Publicado: (2023)

Splenic Volume, an Easy-To-Use Predictor of HCC Late Recurrence for HCC Patients After Hepatectomy
por: Fang, Tongdi, et al.
Publicado: (2022)

Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies
por: Pal Chaudhary, Surendra, et al.
Publicado: (2023)

Comparison between using hepatocellular carcinoma (HCC) risk scores and the HCC national guideline to identify high‐risk chronic hepatitis B patients for HCC surveillance in Thailand
por: Rattananukrom, Chitchai, et al.
Publicado: (2022)

Molecular Signature and Immune Landscape of HCV-Associated Hepatocellular Carcinoma (HCC): Differences and Similarities with HBV-HCC
por: De Battista, Davide, et al.
Publicado: (2021)

Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
por: Kudo, Masatoshi, et al.
Publicado: (2020)

Robotic Liver Resection Versus Percutaneous Ablation for Early HCC: Short- and Long-Term Results
por: Magistri, Paolo, et al.
Publicado: (2020)

Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

MRI in detection of hepatocellular carcinoma (HCC)
por: Digumarthy, Subba R, et al.
Publicado: (2005)

An Overview of Biomarkers and Molecular Signatures in HCC
por: Yim, Seon-Hee, et al.
Publicado: (2010)

Imaging of HCC—Current State of the Art
por: Schraml, Christina, et al.
Publicado: (2015)

Contrast Enhanced MRI in the Diagnosis of HCC
por: Niendorf, Eric, et al.
Publicado: (2015)

Therapeutic Strategies in HCC: Radiation Modalities
por: Gallicchio, R., et al.
Publicado: (2016)

Gender disparity in HCC: Is it the fat and not the sex?
por: Greten, Tim F.
Publicado: (2019)

Incapacitated Capicua in Sorafenib-Resistant HCC
por: Yin, Dingzi, et al.
Publicado: (2020)

Radiotherapy for HCC: Ready for prime time?
por: Bang, Andrew, et al.
Publicado: (2019)

How to improve HCC surveillance outcomes
por: Sherman, Morris
Publicado: (2019)

MicroRNAs in Animal Models of HCC
por: Fornari, Francesca, et al.
Publicado: (2019)

NAFLD-Associated HCC: Progress and Opportunities
por: Geh, Daniel, et al.
Publicado: (2021)

Fontan Liver Lesions: Not Always HCC
por: Haeffele, Christiane, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021)

Emerging Therapies for Hepatocellular Carcinoma (HCC)
por: Chakraborty, Eesha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0vmvs2hiu2lt4qertmrn9t9m6d